[go: up one dir, main page]

PL3174891T3 - Krystaliczna postać rybozydu nikotynamidu - Google Patents

Krystaliczna postać rybozydu nikotynamidu

Info

Publication number
PL3174891T3
PL3174891T3 PL15825253T PL15825253T PL3174891T3 PL 3174891 T3 PL3174891 T3 PL 3174891T3 PL 15825253 T PL15825253 T PL 15825253T PL 15825253 T PL15825253 T PL 15825253T PL 3174891 T3 PL3174891 T3 PL 3174891T3
Authority
PL
Poland
Prior art keywords
crystalline form
nicotinamide riboside
riboside
nicotinamide
crystalline
Prior art date
Application number
PL15825253T
Other languages
English (en)
Inventor
Erik C. Carlson
Michael C. Standen
Westin M. Morrill
Original Assignee
W.R. Grace & Co. - Conn.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3174891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by W.R. Grace & Co. - Conn. filed Critical W.R. Grace & Co. - Conn.
Publication of PL3174891T3 publication Critical patent/PL3174891T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15825253T 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu PL3174891T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028702P 2014-07-24 2014-07-24
EP15825253.6A EP3174891B1 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside
PCT/US2015/041956 WO2016014927A2 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside

Publications (1)

Publication Number Publication Date
PL3174891T3 true PL3174891T3 (pl) 2020-08-10

Family

ID=55163976

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20153772T PL3670522T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu
PL15825253T PL3174891T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20153772T PL3670522T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu

Country Status (7)

Country Link
US (2) US10323058B2 (pl)
EP (2) EP3174891B1 (pl)
CN (1) CN106715454B (pl)
CA (1) CA2956163C (pl)
ES (2) ES2908332T3 (pl)
PL (2) PL3670522T3 (pl)
WO (1) WO2016014927A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428791B (zh) * 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式
PT3331894T (pt) 2015-08-05 2021-04-07 Metro Int Biotech Llc Derivados mononucleotídicos de nicotinamida e suas utilizações
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
AU2017356475B2 (en) 2016-11-11 2023-11-30 ChromaDex Inc. Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018102426A1 (en) 2016-11-29 2018-06-07 University Of Iowa Research Foundation Use of nad precursors for improving maternal health and/or offspring health
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2019126482A1 (en) * 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
EP3794007A1 (en) 2018-05-18 2021-03-24 Roche Diagnostics GmbH (thio)nicotinamide ribofuranoside salts and compositions, methods of making, and uses thereof
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
KR20210108400A (ko) * 2018-12-10 2021-09-02 크로마덱스 아이엔씨. 니코티노일 리보사이드 및 이의 유도체의 결정질 형태 및 이의 제조 방법
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
MX2021010043A (es) * 2019-02-21 2022-07-19 Chromadex Inc Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
CN119462782A (zh) 2019-07-19 2025-02-18 生物合成股份公司 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
EP4214217B1 (en) * 2020-09-15 2024-09-18 Société des Produits Nestlé S.A. Methods for producing dihydronicotinamide riboside from nicotinamide riboside chloride
CN117545488A (zh) 2021-05-27 2024-02-09 麦德龙国际生物科技有限责任公司 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
DK0981534T3 (da) 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
US20040266723A1 (en) 2000-12-15 2004-12-30 Otto Michael J. Antiviral agents for treatment of Flaviviridae infections
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
WO2006001982A2 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
EP1853586B1 (en) 2005-02-18 2013-07-24 AstraZeneca AB Antibacterial piperidine derivatives
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP3730507A1 (en) 2005-11-18 2020-10-28 Cornell Research Foundation, Inc. Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
WO2008075172A2 (en) 2006-12-19 2008-06-26 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2008091710A2 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
JP2011524894A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
US20100015072A1 (en) 2008-06-30 2010-01-21 Christopher Polla Topical Compositions Comprising Isonicotinamide
KR20110026019A (ko) 2008-08-06 2011-03-14 시코르, 인크. 아자시티딘 중간체의 제조 방법
EP2446048A4 (en) 2009-06-23 2013-04-03 Harvard College METHOD AND KITS FOR MEASURING AN ENZYME ACTIVITY
US8933217B2 (en) 2009-07-24 2015-01-13 Amazentis Sa Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
WO2011081942A1 (en) * 2009-12-14 2011-07-07 Cornell University Activation and activators of sirt5
US20130165398A1 (en) 2010-03-29 2013-06-27 Paul Hochegger Concentration-enhancing drink
WO2012004917A1 (ja) 2010-07-06 2012-01-12 Kaminishi Hidenori 神経突起伸長剤
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
JP6284475B2 (ja) 2011-06-29 2018-02-28 ザ ジェネラル ホスピタル コーポレイション 雌性生殖細胞における生体エネルギー状態を増強するための組成物及び方法
EP2726477A4 (en) 2011-06-29 2015-08-26 Harvard College SMALL MOLECULAR CD38 HEMMER AND USE METHOD THEREFOR
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
WO2014011676A1 (en) 2012-07-09 2014-01-16 Tolleth Robert J Prevention of alcohol reaction with dietary supplements
WO2014014828A1 (en) 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) * 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
WO2015061512A1 (en) 2013-10-24 2015-04-30 The Procter & Gamble Company Skin lightening cosmetic compositions and methods
WO2015064988A1 (ko) 2013-10-29 2015-05-07 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
MX385305B (es) 2013-10-30 2025-03-18 Chromadex Inc Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.
EP3068240A4 (en) 2013-11-12 2017-06-14 Ortho-Nutra LLC Theacrine-based supplement and method of use thereof
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
KR20160133529A (ko) 2014-03-13 2016-11-22 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 펙사라민 유도체 및 이의 제조와 사용 방법
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
AU2015270130A1 (en) * 2014-06-02 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
JP2017522314A (ja) 2014-07-17 2017-08-10 ザ スクリプス リサーチ インスティテュート がん治療を向上させるための方法および組成物
CN107428791B (zh) 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式

Also Published As

Publication number Publication date
CN106715454B (zh) 2020-06-16
US10233207B2 (en) 2019-03-19
EP3670522B1 (en) 2022-01-19
EP3670522A1 (en) 2020-06-24
EP3174891A2 (en) 2017-06-07
ES2776395T3 (es) 2020-07-30
CN106715454A (zh) 2017-05-24
EP3174891B1 (en) 2020-01-29
WO2016014927A2 (en) 2016-01-28
US10323058B2 (en) 2019-06-18
EP3174891A4 (en) 2018-05-30
CA2956163C (en) 2023-01-10
US20170210774A1 (en) 2017-07-27
WO2016014927A3 (en) 2016-09-15
US20180086783A1 (en) 2018-03-29
CA2956163A1 (en) 2016-01-28
ES2908332T3 (es) 2022-04-28
PL3670522T3 (pl) 2022-02-21

Similar Documents

Publication Publication Date Title
ZA201705776B (en) Crystalline form of nicotinamide riboside
PL3174891T3 (pl) Krystaliczna postać rybozydu nikotynamidu
IL251560A0 (en) Methods for preparing ribosides
EP3136857A4 (en) Crystalline form of baricitinib
SG10201913200XA (en) Crystalline form of lorlatinib free base
IL246385B (en) Crystalline forms of efitinib di-malate
SI3154526T1 (sl) Trdne oblike sofosbuvira
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
IL246979A0 (en) Crystalline forms of sofosbuvir
IL251863A0 (en) Crystalline forms of ferric-maltol
SI3529236T1 (sl) Kristalinične oblike eravaciklina
EP3207034A4 (en) Anhydrous crystalline form of s-equol
IL253479A0 (en) Crystalline forms of efinconazole
PL3350179T3 (pl) Krystaliczne postacie
HUP1500506A2 (en) Salts of palbociclib
IL249332A0 (en) Crystalline forms of sofosbuvir